Inclusion Criteria:

women aged 35-70 years with all of the following criteria: untreated, histologically
confirmed squamous cell carcinoma of the uterine cervix FIGO stage IB2 or bulky IIA, with
tumor extension limited to within the upper one third of the vaginal wall. Bulky tumor is
defined as (a) a visible cervical tumor with the largest diameter >4 cm or (b) a cervix
expanded to > 4 cm as a result of tumor infiltration by pelvic examination and verified by
magnetic resonance image (MRI), 3-dimensional (D) computed tomography (CT), or 3-D
ultrasound study no suspicious lymph node metastasis as no enlarged lymph node or
extrapelvic spread of cancer detected by MRI, or negative cytologic or histologic study of
the suspicious node(s) (for those also participating PET-CT monitoring response trial,
only abnormal FDG uptake in pelvic node(s) without proven nodal or extrapelvic metastasis
are eligible)

Exclusion Criteria:

Histological or cytological documented pelvic lymph node or extrapelvic metastasis,
concurrent or history of malignant tumor(s) other than treated nonmelanoma skin cancer had
undergone surgical procedure other than cervical biopsy or had received cytotoxic
procedure including chemotherapy, radiotherapy or treatment with biologic response
modifier(s) for the cervical tumor participate in investigational treatment for the
cervical cancer history of allergic reaction to platinum or paclitaxel uncontrolled
intercurrent illness including, but not limited to, ongoing or active infection,
symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or
psychiatric illness/social situations that would limit compliance with study requirements
pregnant or breast feeding women, a urinary pregnancy test must be performed on all
patients who are of child-bearing potential before entering the study and the result must
be negative

-